Microalbuminuria, but not reduced eGFR, is associated with cardiovascular subclinical organ damage in type 2 diabetes

Diabetes and Metabolism

Volumn 40, Issue 1, 2014, Pages 49-55

  Sjoblom P ^a,b,c   Nystrom, F H ^c,d   Lanne T ^c   Engvall, J ^b,c   Ostgren C J ^c  

^a Skärblacka Primary Health Care Centre   (Sweden)

^b Department of Clinical Immunology and Transfusion Medicine   (Sweden)

^c LINKÖPING UNIVERSITY   (Sweden)

^d LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Albuminuria; Atherosclerosis; Cardiovascular disease markers; GFR; Type 2 diabetes

Indexed keywords

ALBUMIN; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; CREATININE; HEMOGLOBIN A1C; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AMBULATORY SYSTOLIC BLOOD PRESSURE; ARTERIAL WALL THICKNESS; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE MONITORING; BLOOD VESSEL DIAMETER; CARDIOVASCULAR DISEASE; CARDIOVASCULAR PARAMETERS; CREATININE URINE LEVEL; DISEASE ASSOCIATION; DISEASE DURATION; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; LEFT VENTRICULAR MASS INDEX; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN URINE LEVEL; PULSE WAVE; SYSTOLIC BLOOD PRESSURE; URINARY EXCRETION;

ALBUMINURIA; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE MARKERS; GFR; TYPE 2 DIABETES;

ALBUMINURIA; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; BLOOD FLOW VELOCITY; BLOOD PRESSURE; CAROTID INTIMA-MEDIA THICKNESS; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY; MALE; MIDDLE AGED; QUESTIONNAIRES; RISK FACTORS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84893731734     PISSN: 12623636     EISSN: 18781780     Source Type: Journal    
DOI: 10.1016/j.diabet.2013.09.008     Document Type: Article

References (35)

1. Gerstein H.C., Mann J.F., Pogue J., Dinneen S.F., Halle J.P., Hoogwerf B., et al. Prevalence and determinants of microalbuminuria in high-risk diabetic and nondiabetic patients patients in the Heart Outcomes Prevention Evaluation Study. Diabetes Care 2000, 23(Suppl. 2):B35-B39.
2. Ärnlöv J., Evans J.C., Meigs J.B., Wang T.J., Fox C.S., Levy D., et al. Low-grade albuminuria and incidence of cardioavascular disease events in nonhypertensive and nondiabetic individuals. The Framingham Heart Study. Circulation 2005, 112:969-975.
3. Gerstein H.C., Mann J.F., Yi Q., Zinman B., Dinneen S.F., Hoogwerf B., et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001, 286:421-426.
4. Ross R. Atherosclerosis - An inflammatory disease. N Engl J Med 1999, 340:115-126.
5. National Kidney Foundation KDOQI Clinical Practice Guidelines for Chronic Kidney Disease: evaluation, classification and stratification. Am J Kidney Dis 2002, 39(Suppl. 1):S1-S266. [http://www.kidney.org/professionals/KDOQI/guidelines_ckd].
6. National Institute for Health and Clinical Excellence (NICE) Clinical guideline 73: chronic kidney disease 2008, National Institute for health and Clinical Excellence (NICE), London, [www.nice.org.uk].
7. Foster M.C., Hwang S.J., Larson M.G., Parikh N.I., Meigs J.B., Vasan R.S., et al. Cross-classification of microalbuminuria and reduced glomerular filtration rate. Associations between cardiovascular disease risk factors and clinical outcomes. Arch Intern Med 2007, 167:1386-1392.
8. Yokoyama H., Oishi M., Kawai K., Sone H., on behalf of the Japan Diabetes Clinical Management Study Group Reduced GFR and microalbuminuria are independently associated with prevalent cardiovascular disease in Type 2 diabetes: JDDM study 16. Diab Med 2008, 25:1426-1432.
9. American Diabetes Association Standards of medical care in diabetes. Diabetes Care 2012, 35(Supplement 1):S34-S35.
10. Levey A.S., Bosch J.P., Lewis J.B., Greene T., Rogers N., Roth D., et al. A more accurate method to estimate glomerular filtration from serum creatinine: a new prediction equation. Ann Intern Med 1999, 130:461-470.
11. Devereux R.B., Reichek N. Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Circulation 1977, 55:613-618.
12. Lang R.M., Berig M., Deveraux R.B., Flachskampf F.A., Foster E., Pellikka P.A., et al. Recommendations for chamber quantification. Eur J Echocardiogr 2006, 7:79-108.
13. de Simone G., Kizer J.R., Chinali M., Roman M.J., Bella J.N., Best L.G., et al. Normalization for body size and population-attributable risk of left ventricular hypertrophy. The Strong Heart Study. Am J Hypertens 2005, 18:191-196.
14. Mancia G., Fagard R., Narkiewicz K., Redón J., Zanchetti A., Böhm M., et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension. J Hypertens 2013, 31:1281-1357.
15. Chronic Kidney Disease Prognosis Consortium Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010, 375:2073-2081.
16. Go A.S., Chertow G.M., Dongjie F., McCulloch C.E., Hsu C. Chronic Kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004, 351:1296-1305.
17. Rigalleau V., Lasseur C., Raffaitin C., Beauvieux M.C., Barthe N., Chauveau P., et al. Normoalbuminuric renal-insufficient diabetic patients. Diabetes Care 2007, 30:2034-2039.
18. Deinum J., Derkx F. Cystatin for estimation of glomerular filtration rateα. Lancet 2000, 356:1624-1625.
19. Rigalleau V., Lasseur C., Perlemoine C., Barthe N., et al. Estimation of glomerular filtration rate in diabetic subjects: Cockcroft formula or Modification of Diet in Renal Disease study equationα. Diabetes Care 2005, 28:838-843.
20. Laurent S., Cockroft J., Van Bortel L., Boutouyrie P., Giannattasio C., Hayoz D., et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 2006, 27:2588-2605.
21. Laurent S., Boutouyrie P., Asmar R., Gautier I., Laloux B., Guize L., et al. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension 2001, 37:1236-1241.
22. Cruickshank K., Riste L., Anderson S.G., Wright J.S., Dunn G., Gosling R.G. Aortic pulse-wave velocity and its relationship to mortality in diabetes and glucose intolerance: an integrated index of vascular function. Circulation 2002, 106:2085-2090.
23. Bouchi R., Babazono T., Mugishima M., Yoshida N., Nyumura I., Toya K., et al. Arterial stiffness is associated with incident albuminuria and decreased glomerular filtration rate in type 2 diabetic patients. Diabetes Care 2011, 34:2570-2575.
24. Yokoyama H., Aoki T., Imahori M., Kuramitsu M. Subclinical atherosclerosis is increased in type 2 diabetic patients with microalbuminura evaluated by intima-media thickness and pulse wave velocity. Kidney Int 2004, 66:448-454.
25. Ito H., Komatsu Y., Mifune M., Antoku S., Ishida H., Takeuchi Y., et al. The estimated GFR, but not the stage of diabetec nephropathy graded by the urinary albumin excretion, is associated with the carotid intima-media thickness in patients with type 2 diabetes mellitus: a cross-sectional study. Cardiovasc Diabetol 2010, 9:18.
26. Watchell K., Olsen M.H., Dahlöf B., Devereux R.B., Kjeldsen S.E., Nieminen M.S., et al. Microalbuminuria in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE Study. J Hypertens 2002, 20:405-412.
27. Watchell K., Ibsen H., Olsen M.H., Borch-Johnsen K., Lindholm L.H., Mogensen C.E., et al. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE Study. Ann Intern Med 2003, 139:901-906.
28. Thomas G., Sehgal A.R., Kashyap S.R., Srinivas T.R., Kirwan J.P., Navaneethan S.D. Metabolic syndrome and kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol 2011, 6:2364-2373.
29. Gobal F., Deshmukh A., Shah S., Mehta J.L. Triad of metabolic syndrome, chronic kidney disease and coronary heart disease with a focus on microalbuminuria. J Am Coll Cardiol 2011, 57:2303-2308.
30. Bayauli M.P., Lepira F.B., Kayembe P.K., ḾBuyamba-Kabangu J.R. Left ventricular hypertrophy and geometry in type 2 diabetes patients with chronic kidney disease. An echocardiographic study. Cardiovasc J Afr 2012, 23:73-77.
31. Nardi E., Palermo A., Mulè G., Cusimano P., Cottone S., Cerasola G. Impact of type 2 diabetes on left ventricular geometry and diastolic function in hypertensive patients with chronic kidney disease. J Hum Hypertens 2011, 25:144-151.
32. Ahmed S.B., Culleton B.F., Tonelli M., Klarenbach S.W., MacRae J.M., Zhang J., et al. Oral estrogen therapy in postmenopausal women is associated with loss of kidney function. Kidney Int 2008, 74:370-376.
33. Lloyd K.D., Barinas-Mitchell E., Kuller L.H., Mackey R.H., Wong E.A., Sutton-Tyrrell K. Common carotid artery diameter and cardiovascular risk factors in overweight or obese postmenopausal women. Int J Vasc Med 2012, 169323. 10.1155/2012/169323.
34. Jensen-Urstad K., Jensen-Urstad M., Johansson J. Carotid artery diameter correlates with risk factors for cardiovascular disease in a population of 55-years-old subjects. Stroke 1999, 30:1572-1576.
35. Crowe E., Halpin D., Stevens P., on behalf of the Guideline Development Group Early identification and management of chronic kidney disease: summary of NICE guidance. BMJ 2008, 337:a1530.